EMEA-000781-PIP01-09 - paediatric investigation plan
sorafenib tosilate
PIPHuman
Estonian is available via eTranslation, the European Commission's machine translation service.
Translate to Estonian | Important information about machine translation
Key facts
- Invented name
- Nexavar
- Nexavar
- Active substance
- sorafenib tosilate
- Therapeutic area
- Oncology
- Decision number
- P/68/2010
- PIP number
- EMEA-000781-PIP01-09
- Pharmaceutical form(s)
- Film-coated tablet
- Condition(s) / indication(s)
- Differentiated thyroid cancer
- Route(s) of administration
- Oral use
- Contact for public enquiries
Bayer Schering Pharma AG
E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com
Country: Germany
Phone: +49 3046815333
Fax: +49 3046815333- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date
- Compliance check done
- Ei